Bryan Johnson received Volostatin, a follistatin gene therapy injected into his oblique muscles to build muscle and slow aging. He's tracking follistatin levels expected to jump from under 10 ng/mL to the 20s, plus biomarkers across 20 organ systems, to measure the therapy's real-time effects on his body.
Okay. Should do, right? Which one are you gonna go after?
That one in the middle.
Good stick.
Thank you.
Look at that flow rate. All right. I just had my blood drawn because I did my first gene therapy 14 days ago. Volostatin. I had two shots in my sides, my obliques. Gene therapy is meant to increase muscle and strength, and we're monitoring 20 other organs. It has effects like slowing speed of aging, reducing epigenetic age. So these three vials we just drew today are going to be processed, and we're going to look at my follistatin levels, my blood. Before I did the gene therapy, I had extensive measurement with MRI and blood and a whole bunch of other things. We're now looking at the levels expressed in my body. So we're hoping to see the FL statin has increased before the therapy was below 10, and so we're hoping they're somewhere in the 20s, maybe even higher range. So we'll see in two days where they're at. It's exciting, though, to track in real time what these gene therapies are doing.
